Two members of Alabama’s congressional delegation – Sen. Richard Shelby and Rep. Gary Palmer – have written the federal Food & Drug Administration on behalf of a Montgomery family whose son has Duchenne muscular dystrophy, a rare degenerative disease.
The pair of lawmakers hopes to amplify the voice of Scott and Tracy Griffin, whose son Gabe Griffin suffers from Duchenne as well as terrible side effects from a class of drugs call corticosteroids, which helps delay the worst muscular effects of the disease, but does not address the ailment’s causes.
Shelby and Palmer are asking for a meeting with an FDA Commissioner with the Griffins in Washington, D.C.
“Sadly, Gabe’s muscles will continue to deteriorate until he can’t walk, breathe or eat by himself,” Shelby wrote in a missive co-authored by Palmer. “Without access to new treatment, these devastating effects of Duchenne will impact Gabe well before he turns twenty years old.”
“Gabe is currently prescribed FDA-approved steroids with side effects of stunted growth, extreme sensitivity to light, postponed puberty, and brittle bones. However these drugs do nothing to target the underlying problem, a missing protein, which causes Duchenne.”
Towards the end of getting patient feedback directly to the agency about refining available drugs, Palmer said, a meeting is in order.
Griffin is the eponym of the “Gabe Griffin Right to Try Act” signed into law by Gov. Robert Bentley in June, which removes restrictions on the prescription of experimental drugs if willing patients sign a waiver which releases the state from liability.
The Griffin family responded to an FDA public comment invitation earlier this summer, where according to a release from their foundation Hope for Gabe, they submitted remarks that reflect a range of views which include:
- Opposition to randomized placebo-controlled trials for Duchenne patients, with a reminder that the FDA’s own website states that ‘a child should not be deprived of a treatment in a clinical trial that is necessary for the child’s health;”
- A request for the FDA to use its authority to approve [experimental drugs]Eteplirsen and Drisapersen and accelerate the approval of subsequent and follow-on drugs using the same underlying approach;
- A request for the FDA to encourage an effort to collect and publish data regarding the size of different subgroups of patients within the Duchenne and related dystrophinopathy communities; and
- Support for the FDA’s authority to use “fewer, smaller, or shorter clinical trials for the intended patient population or targeted subpopulation without compromising or altering the high standards of the FDA for the approval of drugs.”
Palmer formally requested a meeting for the Griffins with an FDA agent “at a mutually convenient time in the future.”